TELA Bio, Inc. - Common stock (TELA)
Frequently Asked Questions About TELA Bio, Inc. - Common stock (TELA)
How can healthcare providers access TELA Bio’s products?
Healthcare providers can access TELA Bio's products through a network of authorized distributors and direct sales representatives. The company provides educational resources and training to surgeons and medical staff to ensure proper use and understanding of its innovative surgical solutions.
How can investors learn more about TELA Bio’s financial performance?
Investors can learn more about TELA Bio's financial performance by reviewing the company’s quarterly and annual earnings reports, which are filed with the SEC and are accessible on the company's investor relations website. Additionally, TELA Bio hosts periodic investor calls and webcasts to discuss financial updates and business strategy.
How does TELA Bio approach sustainability?
TELA Bio approaches sustainability by designing products with eco-friendly materials and focusing on responsible manufacturing practices. The company recognizes the importance of reducing its environmental impact and aims to incorporate sustainable practices into its operations wherever possible.
How does TELA Bio differentiate itself from competitors?
TELA Bio differentiates itself by focusing on the unique combination of biological and synthetic materials in its products, allowing for enhanced tissue regeneration and reduced complication rates. The company's emphasis on innovation, clinical trials, and responsiveness to surgeon feedback sets it apart in the competitive surgical device market.
How does TELA Bio ensure product quality and safety?
TELA Bio ensures product quality and safety through rigorous compliance with regulatory standards set forth by agencies such as the FDA. The company follows strict quality control processes throughout the product development lifecycle, including extensive testing and validation to safeguard patient outcomes.
Is TELA Bio publicly traded?
Yes, TELA Bio, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol TELA. The company went public in 2019, providing it with greater access to capital for research and development, as well as operational growth.
What are TELA Bio’s primary products?
TELA Bio's primary products include its OviTex family of biologic mesh devices, which are designed for use in hernia repair and other soft tissue reconstruction procedures. These meshes combine the strength of synthetic materials with the regenerative potential of human tissue, enhancing healing and reducing complications.
What are the future growth plans for TELA Bio?
TELA Bio plans to expand its product offerings and continue its growth by entering new markets and exploring additional surgical applications. The company aims to enhance its clinical evidence base, increase distribution networks, and strengthen partnerships with healthcare providers to drive adoption of its products.
What are the regulatory approvals that TELA Bio has received?
TELA Bio has received several regulatory approvals for its products, including 510(k) clearance from the FDA for its OviTex line of products. These approvals signify that TELA’s devices meet stringent safety and efficacy standards, allowing them to be marketed in the United States.
What clinical evidence supports TELA Bio's products?
TELA Bio's products are supported by various clinical studies that demonstrate their efficacy and safety in surgical applications. The company continuously invests in clinical research to gather data and validate the performance of its implants, helping to bridge the gap between development and market adoption.
What does TELA Bio, Inc. do?
TELA Bio, Inc. is a medical technology company focused on developing and commercializing innovative surgical solutions, particularly in the field of regenerative medicine. The company's primary offerings are surgical implants made from bio-compatible materials designed to support tissue regeneration and improve surgical outcomes in various surgical applications.
What is TELA Bio's approach to product development?
TELA Bio's approach to product development involves leveraging biomaterials science to create innovative solutions that meet the needs of surgeons and patients. The company prioritizes clinical evidence and regulatory compliance, ensuring its products not only meet high-quality standards but also deliver real-world performance.
What is TELA Bio's commitment to innovation?
TELA Bio is deeply committed to innovation in the surgical field. The company invests in advanced research and development to create novel products that leverage cutting-edge science and technology, intending to improve surgical techniques and patient recovery experiences.
What is TELA Bio's vision for the future?
TELA Bio's vision for the future is to become a leading player in the surgical implant market by continuously innovating and expanding its product portfolio. The company aims to enhance patient care through advancements in surgical techniques and to positively impact the lives of patients undergoing surgical procedures.
What markets does TELA Bio serve?
TELA Bio serves the global surgical market, specifically focusing on hernia repair, breast reconstruction, and other soft tissue repair procedures. Their products are aimed at surgeons in hospitals and surgical centers seeking innovative solutions to improve patient outcomes.
What role does TELA Bio play in the regenerative medicine field?
TELA Bio plays a significant role in the regenerative medicine field by developing products that foster natural healing and tissue regeneration. The company’s biomaterials are specifically designed to interact positively with the body's natural healing processes, offering improved solutions for surgeons and better outcomes for patients.
What type of research collaborations does TELA Bio pursue?
TELA Bio pursues research collaborations with academic institutions, medical research organizations, and other industry partners. These collaborations aim to advance the understanding of regenerative medicine and to facilitate the development of new applications for TELA's innovative products.
When was TELA Bio, Inc. founded?
TELA Bio, Inc. was founded in 2014 by a team of professionals with expertise in biomaterials and regenerative medicine. Since its inception, the company has aimed to address unmet surgical needs through the development of advanced biological meshes and other surgical products.
Where is TELA Bio, Inc. headquartered?
TELA Bio, Inc. is headquartered in Malvern, Pennsylvania. This strategic location provides the company access to a strong biotech and medical device ecosystem, facilitating collaborations and partnerships within the industry.
Who are the key executives at TELA Bio?
The key executives at TELA Bio include President and CEO Antony E. Lanza, who has extensive experience in the medical device industry. Other members of the management team bring diverse expertise in business development, finance, and regulatory affairs, contributing to the company's mission.
What is the current price of TELA Bio, Inc. - Common stock?
The current price of TELA Bio, Inc. - Common stock is 1.190
When was TELA Bio, Inc. - Common stock last traded?
The last trade of TELA Bio, Inc. - Common stock was at 3:31 pm EDT on April 3rd, 2025
What is the market capitalization of TELA Bio, Inc. - Common stock?
The market capitalization of TELA Bio, Inc. - Common stock is 46.87M
How many shares of TELA Bio, Inc. - Common stock are outstanding?
TELA Bio, Inc. - Common stock has 39.39M shares outstanding.